Search results for "Precursor cell"

showing 10 items of 116 documents

Identification and molecular characterization of CALM/AF10fusion products in T cell acute lymphoblastic leukemia and acute myeloid leukemia

2000

The t(10;11)(p12-p13;q14-q21) observed in a subset of patients with either acute lymphoblastic leukemia or acute myeloid leukemia has been shown to result in the fusion of AF10 on chromosome 10 with CALM (also named CLTH) on chromosome 11. AF10 was originally identified as a fusion partner of MLL in the t(10;11)(p12-p13;q23) observed in myeloid leukemia. CALM is a newly isolated gene, cloned as the fusion partner of AF10 in the monocytoid cell line, U937. In order to understand the relationship between MLL, AF10, CALM and the leukemic process, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction were used to study a series of nine leukemia patients with a t…

AdultMaleCancer ResearchMyeloidOncogene Proteins FusionChromosomal translocationBiologyImmunophenotypingImmunophenotypinghemic and lymphatic diseasesAcute lymphocytic leukemiamedicineHumansCloning MolecularChildneoplasmsIn Situ Hybridization FluorescenceDNA PrimersABLBase Sequencemedicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionMyeloid leukemiaHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseVirologyLeukemiamedicine.anatomical_structureOncologyLeukemia MyeloidAcute DiseaseCancer researchFluorescence in situ hybridizationLeukemia
researchProduct

Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8 + T Cells To Predict CMV DNAemia Clearance in …

2014

ABSTRACT It is uncertain whether monitoring plasma ganciclovir (GCV) levels is useful in predicting cytomegalovirus (CMV) DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients. In this observational study, including 13 episodes of CMV DNAemia treated with intravenous (i.v.) GCV or oral valganciclovir, we showed that monitoring trough plasma GCV levels does not reliably predict response to therapy. Rather, immunological monitoring (pp65 and immediate-early [IE]-1-specific gamma interferon [IFN-γ]-producing CD8 + T cells) appeared to perform better for this purpose.

AdultMaleGanciclovirvirusesCongenital cytomegalovirus infectionCytomegalovirusCD8-Positive T-LymphocytesClinical TherapeuticsViral Matrix ProteinsInterferon-gammamedicineHumansValganciclovirCytotoxic T cellPharmacology (medical)GanciclovirMultiple myelomaPharmacologybusiness.industryLymphoma Non-HodgkinAnemia Aplasticvirus diseasesValganciclovirMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaPhosphoproteinsmedicine.diseaseTransplant RecipientsLeukemia Myeloid AcuteLeukemiaInfectious DiseasesCytomegalovirus InfectionsDNA ViralImmunologyFemaleStem cellMultiple MyelomabusinessCD8Stem Cell Transplantationmedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

Fatal sepsis due to mycobacterium tuberculosis after allogeneic bone marrow transplantation.

2001

Mycobacterium tuberculosis is a serious, but rare infectious complication after allogeneic bone marrow transplantation. We describe a case of fatal sepsis due to Mycobacterium tuberculosis after allogeneic bone marrow transplantation for Philadelphia chromosome-positive ALL. The diagnosis was made after BAL. Although broad-spectrum antituberculous therapy was started immediately after diagnosis, blood cultures became positive for Mycobacterium tuberculosis. The patient developed severe pyrexias and finally died of multi-organ failure. Rapid progression of mycobacterial infection should be considered in patients post BMT with unexplained fever, particularly in patients from endemic areas.

AdultMaleMycobacterium tuberculosisSepsisFatal OutcomeAcute lymphocytic leukemiamedicineHumansTransplantation HomologousTuberculosisIn patientAutogenous boneBone Marrow TransplantationTransplantationbiologybusiness.industryMarrow transplantationHematologyMycobacterium tuberculosisPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseasebiology.organism_classificationmedicine.anatomical_structureImmunologyBone marrowbusinessComplicationBone marrow transplantation
researchProduct

Differential expression of specific microRNA and their targets in acute myeloid leukemia

2010

Acute myeloid leukemia (AML) the most common acute leukemia in adults is characterized by various cytogenetic and molecular abnormalities. However, the genetic etiology of the disease is not yet fully understood. MicroRNAs (miRNA) are small noncoding RNAs which regulate the expression of target mRNAs both at transcriptional and translational level. In recent years, miRNAs have been identified as a novel mechanism in gene regulation, which show variable expression during myeloid differentiation. We studied miRNA expression of leukemic blasts of 29 cases of newly diagnosed and genetically defined AML using quantitative reverse transcription polymerase chain reaction (RT-PCR) for 365 human miR…

AdultMaleNPM1Down-RegulationBiologySettore MED/15 - Malattie Del SangueYoung Adulthemic and lymphatic diseasesmicroRNAmedicineGene silencingHumansLeukemia microarray data microRNAGranulocyte Precursor CellsAgedCell ProliferationGeneticsRegulation of gene expressionAged 80 and overAcute leukemiaReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingCore Binding FactorsMyeloid leukemiaNuclear ProteinsCell DifferentiationHematologyMiddle Agedmedicine.diseaseUp-RegulationGene expression profilingGene Expression Regulation NeoplasticLeukemiaLeukemia Myeloid AcuteMicroRNAsfms-Like Tyrosine Kinase 3Case-Control StudiesMutationFemaleSettore SECS-S/01 - StatisticaNucleophosmin
researchProduct

Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation

2016

Abstract Monitoring of minimal residual disease (MRD) or chimerism may help guide pre-emptive immunotherapy (IT) with a view to preventing relapse in childhood acute lymphoblastic leukemia (ALL) after transplantation. Patients with ALL who consecutively underwent transplantation in Frankfurt/Main, Germany between January 1, 2005 and July 1, 2014 were included in this retrospective study. Chimerism monitoring was performed in all, and MRD assessment was performed in 58 of 89 patients. IT was guided in 19 of 24 patients with mixed chimerism (MC) and MRD and by MRD only in another 4 patients with complete chimerism (CC). The 3-year probabilities of event-free survival (EFS) were .69 ± .06 for …

AdultMaleOncologymedicine.medical_specialtyNeoplasm ResidualAdolescentmedicine.medical_treatmenteducationDiseaseRelapse preventionChimerismYoung Adult03 medical and health sciences0302 clinical medicineRecurrenceGermanyInternal medicineSecondary PreventionHumansTransplantation HomologousMedicineddc:610ChildChildhood Acute Lymphoblastic LeukemiaImmunosuppression TherapyTransplantationbusiness.industryHematopoietic Stem Cell TransplantationRetrospective cohort studyHematologyImmunotherapyPrecursor Cell Lymphoblastic Leukemia-LymphomaSurvival AnalysisMinimal residual diseaseSurgeryTransplantationChild PreschoolLymphocyte Transfusion030220 oncology & carcinogenesisCohortFemaleImmunotherapybusiness030215 immunologyBiology of Blood and Marrow Transplantation
researchProduct

Association of childhood cancer with factors related to pregnancy and birth

1999

It has been hypothesized that risk factors of childhood cancers may already operate during the prenatal and neonatal period. Results of previous epidemiological studies have been inconsistent.During 1992-1997 a large case-control study on childhood cancers and a variety of potential risk factors was conducted in Germany. Cases were ascertained by the German Childhood Cancer Registry. Each case was matched to a population-based control of the same age and gender, sampled from the district where the case lived at the date of diagnosis. For the analyses, 2358 cases and 2588 controls were available.Risk of childhood acute leukaemia increased with maternal ageor =20 years at time of delivery (od…

AdultMalePediatricsmedicine.medical_specialtyAdolescentHormone Replacement TherapyEpidemiologyBirth weightPopulationBone NeoplasmsSoft Tissue NeoplasmsPrenatal careCentral Nervous System NeoplasmsPregnancyRisk FactorsGermanyOdds RatiomedicineBirth WeightHumansRegistriesRisk factorChildeducationRetrospective Studieseducation.field_of_studyChildhood Cancer RegistryPregnancybusiness.industryLymphoma Non-HodgkinSmokingInfant NewbornCase-control studyInfantGeneral MedicineOdds ratioPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseParityMaternal ExposureChild PreschoolPrenatal Exposure Delayed EffectsFemalebusinessMaternal AgeInternational Journal of Epidemiology
researchProduct

Survival of Adults with Acute Lymphoblastic Leukemia in Germany and the United States

2014

BackgroundAdulthood acute lymphoblastic leukemia (ALL) is a rare disease. In contrast to childhood ALL, survival for adults with ALL is poor. Recently, new protocols, including use of pediatric protocols in young adults, have improved survival in clinical trials. Here, we examine population level survival in Germany and the United States (US) to gain insight into the extent to which changes in clinical trials have translated into better survival on the population level.MethodsData were extracted from the Surveillance, Epidemiology, and End Results database in the US and 11 cancer registries in Germany. Patients age 15-69 diagnosed with ALL were included. Period analysis was used to estimate…

AdultMalePediatricsmedicine.medical_specialtyAdolescentNon-Clinical MedicineEpidemiologyScienceLymphoblastic LeukemiaBiostatisticsHematologic Cancers and Related DisordersGermanyLeukemiasEpidemiologyHumansMedicineStatistical MethodsYoung adultSurvival analysisAgedHealth Care PolicyMultidisciplinaryRelative survivalbusiness.industryStatisticsQRCancers and NeoplasmsCancerHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaAcute Lymphoblastic Leukemiamedicine.diseaseSurvival AnalysisUnited StatesClinical trialOncologyUnited States ; age groups ; cancer treatment ; German people ; Germany ; cancer detection and diagnosis ; acute lymphoblastic leukemia ; leukemiasMedicineFemaleHealth StatisticsbusinessMathematicsResearch ArticleRare diseasePLoS ONE
researchProduct

Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease

2002

The feasibility of nonmyeloablative stem cell transplantation (NST) was evaluated in 22 adults with high-risk ALL. 16/22 patients had advanced disease and 11/22 had Ph+ ALL. Eleven patients received NST as first stem cell transplantation (SCT). Eleven patients had relapses after allogeneic or autologous SCT and underwent a salvage NST. 18/22 patients (82%) engrafted after NST. 13/16 patients (81%) with active disease reached complete remission (CR). 11 of 13 patients developed GVHD. After first NST 10/11 patients (91%) engrafted. Six of seven patients with active disease reached CR. Three of five relapsing patients reached subsequent CR after donor lymphocyte infusions, termination of immun…

AdultMaleRiskMelphalanCancer Researchmedicine.medical_specialtyTransplantation Conditioningmedicine.medical_treatmentSalvage therapyGraft vs Leukemia EffectPilot ProjectsAcute lymphocytic leukemiamedicineHumansPhiladelphia ChromosomeSurvival rateSalvage TherapyChemotherapybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationImmunosuppressionHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseCombined Modality TherapySurvival AnalysisSurgeryFludarabineSurvival RateTransplantationsurgical procedures operativeOncologyDisease ProgressionFeasibility StudiesFemalebusinessmedicine.drugLeukemia
researchProduct

Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia

2013

Background and Objective Increased expression of fetal hemoglobin (HbF) may ameliorate the clinical course of hemoglobinopathies like sickle cell disease (SCD) and β-thalassemia. Hydroxyurea (HU) can stimulate HbF production in these diseases but the response is highly variable indicating the utility of developing an in vitro test to predict the patient's response to HU. We assessed whether the HbF response of patients with SCD and thalassemia intermedia (TI) to HU correlates with HBG (both γ-globin genes) expression in their cultured erythroid progenitors following exposure to HU. Patients and Methods We exposed primary erythroid cultures from peripheral blood mononuclear cells from 30 pat…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesCellPrimary Cell CultureGene ExpressionAnemia Sickle CellBiologyPeripheral blood mononuclear cellhydroxyurealiquid erythroid cultureYoung AdultIn vivohemic and lymphatic diseasesFetal hemoglobinmedicineHumansgamma-GlobinsRNA MessengerFetal HemoglobinAgedErythroid Precursor CellsMessenger RNAbeta-ThalassemiaBeta thalassemiaHematologyGeneral MedicineMiddle Agedmedicine.diseaseb-thalassemiaMolecular biologyReal-time polymerase chain reactionmedicine.anatomical_structureTreatment OutcomeCell cultureFemalesickle cell disease
researchProduct

Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therap…

2002

In acute lymphoblastic leukemia (ALL), treatment with granulocyte colony stimulating factor (G-CSF) during remission induction shortens granulocytopenia and may decrease morbidity due to infections. However, the optimal timing of G-CSF administration after chemotherapy is not known. In a prospective randomized multi-center study, adult ALL patients were treated with high-dose ARA-C [HDAC, 3 g/m(2) bid (1 g/m(2) bid for T-ALL) days 1-4] and mitoxantrone (MI 10 mg/m(2) days 3-5). They were randomized to receive recombinant human G-CSF (Lenograstim) 263 micro g/day SC starting either from day 12 (Group 1) or day 17 (Group 2). Fifty-five patients (41 male, 14 female) with a median age of 34 yea…

AdultMalemedicine.medical_specialtyNeutropeniaAdolescentHematopoietic growth factormedicine.medical_treatmentOpportunistic InfectionsNeutropeniaGastroenterologyDrug Administration Schedulelaw.inventionRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansProspective StudiesChemotherapyMitoxantroneHematologybusiness.industryCytarabineHematologyGeneral MedicineMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseHematopoiesisSurgeryGranulocyte colony-stimulating factorLenograstimTreatment OutcomeFemalebusinessmedicine.drugAnnals of Hematology
researchProduct